Journal of Alzheimer's Disease

Despite extensive knowledge of the progressive sequence of cognitive and functional deficits in Alzheimer's Disease (AD), the impact of neurodegeneration on the conscious experience of patients remains largely unexplored. Understanding how the content of consciousness, particularly perceptual awareness, changes with the progression of AD is crucial to enable meaningful person-centred care. This is especially important in severe AD when impairments in language and other cognitive domains mean people are unable to report their experiences. We investigated whether electrophysiological (EEG) and fMRI signatures of perceptual awareness described in healthy older people are present in people with mild-moderate and severe AD using two "no-report" paradigms. Firstly, a visual masking paradigm examined visual awareness negativity (VAN) and late positive (LP) electrophysiological responses and activation in visual cortex and fronto-parietal regions that are characteristically associated with conscious perception of faces; and second, a complex audio-visual (movie) task examined activation in fronto-parietal networks previously associated with perceptual awareness. In healthy older controls we found cortical responses characteristic of awareness in both EEG and fMRI modalities, with VAN and LP markers and widespread occipital, fusiform face area and fronto-parietal activation. In people with mild-moderate AD, there were significant reductions in VAN and LP markers and reduced fronto-parietal activation. In participants with severe AD, who were behaviourally minimally responsive, there was only limited evidence of presence of frontoparietal markers of perceptual awareness, however this may reflect attentional and task insensitivity in people with advanced dementia. These results demonstrate that the brain mechanisms associated with perceptual awareness become increasingly impaired with progression of AD. Specifically, involvement of frontoparietal networks is reduced in AD, which may reflect reduced higher-level awareness. This suggests AD should be considered a disorder of consciousness and should motivate further investigation into the dimensions of awareness affected by the disorder with implications for treatment and management of people with dementia.

INTRODUCTION: The Diabetes Prevention Program (DPP) was a randomized clinical trial designed to prevent type 2 diabetes (T2D) in adults with prediabetes. The DPP Outcomes Study (DPPOS) is the 30-year follow-up of this cohort, focusing on T2D, prediabetes, and related complications. Cognitive assessments began in 2009 and expanded in 2022 to examine cognitive impairment, including Alzheimer's disease (AD) and AD related dementias (ADRD), in the surviving cohort. To support these aims, the National Alzheimer's Coordinating Center Uniform Data Set version 3 (NACC-UDSv3), the standardized framework used by Alzheimer's Disease Research Centers, was implemented in DPPOS in 2022 to enable data sharing with NACC. These forms were complemented by cognitive tests administered in DPPOS. We aimed to integrate the NACC-UDSv3 into the existing longitudinal DPPOS framework while maintaining fidelity to its structure and developing automated reports to streamline cognitive outcomes adjudication. METHODS: Items from the 16 NACC-UDSv3 data forms were compared with those already collected within DPPOS to integrate overlapping similar items, add missing NACC-UDSv3 items, and create a dataset harmonized with NACC-UDSv3. Forms were adapted for electronic data capture (EDC) using the MIDAS (Multimodal Integrated Data Acquisition System, George Washington University). Automated reports integrated current and prior neuropsychological scores to support adjudications. In the first wave of the DPPOS-AD/ADRD study, 1561 cognitive adjudications were successfully completed using the harmonized DPPOS and NACC-UDSv3 data implemented into MIDAS. DISCUSSION: The DPPOS-AD/ADRD project demonstrated that NACC-UDSv3 can be successfully integrated into a long-standing longitudinal cohort not originally designed for AD/ADRD research. The harmonization, electronic capture, and automated adjudication processes may provide a practical framework for other cohorts seeking to incorporate NACC-UDSv3 to align with national AD/ADRD research standards.

The APOE gene is a critical determinant of human healthspan and longevity, with the rare{varepsilon} 2 allele traditionally viewed as a universal protective factor against Alzheimer s disease (AD) and a driver of exceptional lifespan. However, this protective paradigm is predominantly derived from European-centric cohorts, leaving the evolutionary and clinical impacts of{varepsilon} 2 across diverse, highly admixed populations largely unknown due to a lack of local ancestry (LA) resolution. To investigate how local genomic backgrounds modulate APOE survival dynamics we analyzed two Brazilian sample collection of older adults from Sao Paulo city: the Biobank for Aging Studies (BAS, n = 716), a post-mortem autopsy study of naturally deceased individuals; and the Health, Well-being and Aging Study (SABE, n = 952), a census-based elderly sample collection. We evaluated deviations from Hardy-Weinberg equilibrium (HWE) using robust permutation-based models to capture ongoing selective and mortality pressures at the APOE locus. While global APOE frequencies adhered to HWE, integrating LA unveiled striking, mirrored ancestral deviations. Our findings reveal that APOE {varepsilon}2 homozygotes with African ancestry significantly contribute to deviations from HWE in the BAS, with an excess of {varepsilon}2AFR/{varepsilon}2AFR homozygotes observed (p = 0.0196). These distinct HWE deviations demonstrate that an African LA background acts as a genetic buffer, attenuating the phenotypic extreme effects of APOE alleles. Furthermore, we observed an excess of the{varepsilon} 4 European haplotypes in the BAS, which is consistent with a mortality pressure allelic effect in the European LA context. Conversely, the{varepsilon} 4AFR/{varepsilon}4AFR combination was overrepresented in the SABE. While this buffering mechanism mitigates{varepsilon} 4 toxicity, it simultaneously dampens the exceptional longevity advantage typically conferred by the{varepsilon} 2 allele, leading to its neutral accumulation in the post-mortem cohort. Our study challenges the "one-size-fits-all" assumption of APOE biomarkers, demonstrating that{varepsilon} 2 protective mechanisms are context-dependent and modulated by local genomic backgrounds in admixed populations.

Background: ACE variants are genetic risk factors for Alzheimer's disease (AD), potentially through reduced enzymatic activity and impaired amyloid {beta} hydrolysis. Objectives: To create a publicly available database of ACE variants relevant to ACE deficiency and AD, and to estimate the population frequency of damaging ACE variants and their impact on blood ACE levels. Methods: ACE variants were compiled from literature, public databases (VarSome, dbSNP, ClinVar, gnomAD), and sequencing data (WES/WGS) from 5147 Russian individuals. Variants were classified using a consensus in silico score (AlphaMissense, MetaRNN, EVE). Blood ACE levels were measured in 330 carriers of 64 different ACE mutations. Results: We identified 1682 unique ACE variants. Of these, 608 (36.2%) were classified as functionally damaging, including 17 signal peptide, 210 loss of function, and 381 missense variants. The estimated carrier frequency of damaging ACE variants was 2 % (1/50). Notably, 24 variants associated with experimentally confirmed reductions in blood ACE levels had a combined estimated carrier frequency of 3.9 % in the general population, calculated from cumulative gnomAD v4.1.0 allele frequencies under a rare-variant independence model. An open-access browser is available at https://ace-browser.com/. Conclusions: Variants associated with reduced blood ACE levels were estimated to be carried by approximately 1 in 25 individuals in the general population. This frequency is of the same order of magnitude as the 13.2% prevalence of Alzheimer's dementia in individuals aged 75-84 years (Alzheimer's Association, 2025), consistent with the hypothesis that ACE deficiency may represent an underrecognized contributor to late-onset AD susceptibility. The ACE mutations-AD browser and integrated genotype-phenotype data presented here provide a novel resource for future basic, translational, and clinical research on ACE-dependent AD.

INTRODUCTION: Dementia, particularly Alzheimer disease (AD), is a major global health challenge, with prevalence projected to reach 150 million cases by 2050. AD is characterized by progressive cognitive decline linked to neuroinflammation and neurodegeneration. Non-steroidal anti-inflammatory drugs (NSAIDs) have been explored as potential neuroprotective agents, particularly diclofenac, which has been proposed to modulate microglial inflammasome signaling. However, prior studies investigating NSAIDs in AD have yielded inconsistent findings. We therefore reexamined the relationship between selected NSAIDs and dementia outcomes in a large longitudinal cohort from the National Alzheimer Coordinating Center (NACC). METHODS: We analyzed cross-sectional and longitudinal data from the NACC database collected between 2005 and 2022. Associations between NSAID exposure and dementia, AD, and cognitive trajectories were examined. Propensity score matching was performed to compare NSAID users with matched non-users while adjusting for demographic and clinical confounders. Longitudinal mixed-effects models were used to assess cognitive decline based on Montreal Cognitive Assessment (MoCA) scores. RESULTS: Among 47,165 participants, diclofenac and naproxen use were associated with a lower prevalence of dementia and AD compared with matched non-users, whereas etodolac showed no significant associations. Diclofenac users demonstrated reduced odds of dementia and AD. Naproxen showed similar cross-sectional associations. In longitudinal modeling, diclofenac users had a significantly slower rate of cognitive decline than non-users. DISCUSSION: These findings suggest a compound-specific association between NSAID use and AD, with diclofenac potentially modulating disease progression through anti-inflammatory mechanisms. The observed modulation of longitudinal cognitive decline supports further investigation of inflammatory pathways, including microglial and inflammasome signaling, as therapeutic targets in biomarker-defined AD populations.

Alzheimer's disease is characterized by progressive cognitive decline and early cerebrovascular dysfunction, including impaired neurovascular coupling (NVC) and reduced cerebral blood flow (CBF). Tau pathology is a major driver of these deficits, yet therapeutic strategies targeting tau-induced neurovascular dysfunction remain limited. The M1 muscarinic acetylcholine receptor (M1 mAChR) is a promising therapeutic target because of its critical role in cognition. We previously demonstrated that pharmacological activation of M1 mAChR improves cognitive function and neuronal survival in amyloid-based Alzheimer's disease mouse models through sex-specific mechanisms. However, whether M1 mAChR activation restores tau-mediated NVC deficits remains unknown. P301S mice were used as a model of tauopathy. Cognitive function was evaluated using the novel object recognition and Morris water maze tests, and NVC was assessed by measuring whisker stimulation-induced changes in CBF using laser speckle contrast imaging. Following baseline measurements, mice received an acute intraperitoneal injection of VU0486846, a selective M1 mAChR positive allosteric modulator (3 mg/kg), and CBF responses were reassessed over time. P301S tau mice exhibited impaired recognition and spatial memory functions, associated with reduced whisker stimulation-induced increase in CBF, indicative of impaired NVC response, while acute treatment with VU0486846 reversed these changes in NVC. This rescuing effect of VU0486846 was observed earlier in female tau mice compared to males, suggesting a sex-biased effect of M1 mAChR modulation. These findings demonstrate that M1 mAChR positive allosteric modulation reverses tau-induced neurovascular dysfunction, supporting M1 mAChR activation as a promising disease-modifying approach for Alzheimer's disease. The earlier improvement observed in females further suggests that therapeutic efficacy is influenced by biological sex.

BACKGROUND: Aging is associated with a progressive decline in cognitive performance and functional autonomy, both closely related to frailty. Understanding the interrelation between these domains is essential to identify modifiable factors influencing cognitive impairment in older adults. OBJECTIVES: To evaluate the relationship between physical frailty, cognitive performance, and functional dependence, and to identify sociodemographic and clinical variables associated with cognitive impairment in community-dwelling older adults. DESIGN: Cross-sectional study. SETTING: FREEDOM-LNA cohort, a population-based study conducted by the University Hospital of Limoges, France. PARTICIPANTS: A total of 753 community-dwelling older adults aged [≥]75 years, or [≥]65 years with at least two comorbidities, were included. MEASUREMENTS: Cognitive function was assessed using the Mini Mental State Examination (MMSE), 5-word test (5WT), clock drawing test (CDT), and verbal fluency tests. Frailty was defined according to Frieds physical criteria, and functional independence was evaluated using ADL and IADL scales. Sociodemographic, clinical, and lifestyle factors were analyzed using multivariate models to identify predictors of cognitive impairment. RESULTS: Of the participants, 34.4% had a pathologic MMSE, 46.0% failed the CDT, 68.0% the verbal fluency test, and 17.0% the 5WT. Cognitive performance was significantly lower among frail compared to prefrail and robust individuals. Older adults with pathologic cognition were more frequently dependent in activities of daily living. Independent predictors of poor cognitive performance included non-modifiable factors (age, sex, education) and modifiable ones (low BMI, hypertension, alcohol consumption, smoking, and polypharmacy). CONCLUSIONS: Cognitive impairment was highly prevalent among frail older adults and was strongly associated with loss of independence. Interventions targeting modifiable risk factors such as low BMI, hypertension, alcohol consumption, and smoking may help preserve cognitive and functional abilities in aging populations. Interventions to improve BMI and reduce alcohol consumption, smoking, and hypertension may preserve cognition in older adults.

Persistent racial disparities in dementia raise concerns regarding the validity and generalizability of existing prognostic models across diverse populations. We evaluated the utility of the 2024 Lancet Commission risk factors and resting heart rate (RHR) for race-specific dementia risk prediction using data from 55,004 participants in the National Alzheimer's Coordinating Center cohort. Cox proportional hazards and Random Survival Forest (RSF) models were developed separately for Black, White, Asian, and American Indian participants to predict 1-, 3-, and 5-year time to dementia. RSF consistently outperformed Cox models across all racial groups and prediction horizons, achieving 5-year AUCs of 0.88-0.91 compared with 0.69-0.81 for Cox models. Inclusion of RHR modestly and consistently improved predictive performance across racial groups. Predictor importance varied between racial groups, suggesting heterogeneity in dementia risk profiles and disease presentation. These findings support the potential utility of RHR as a complementary prognostic biomarker and highlight the importance of equitable, personalized dementia risk prediction across diverse populations.

Background & Methods: The multifaceted physical nature of heritable cognitive impairment in dementia presents significant challenges for traditional linear frameworks attempting to model synergistic risk. While various loci are identified as contributing to neurocognitive disparities, the emergent phenotypic expression and associated predictive value relative to standard clinical baselines require further investigation. To facilitate dimensional reduction of complex genetic data into identifiable phenotypes, Generalized Low Rank Modeling (GLRM) and K-means clustering are applied to participant data from the Alzheimer's Disease Neuroimaging Initiative (ADNI). The utility of these derived archetypes and clusters is assessed, stratifying variance for Mini-Mental State Examination (MMSE) performance. Utilizing generalized additive modeling (GAM) and partial eta squared (p2) effect size, the derived genetic features are compared with other predictors including age, educational attainment, gender, and raw, genetic variant carriage dimensions. Results & Conclusion: In accordance with the hypothesized empirical regularity, age and education persist as primary predictors of MMSE performance. The unsupervised machine learning pipeline successfully identified a composite genetic cluster that emerged as an influential predictor in terms of relative magnitude (p2). Centroid analysis of the GLRM subspace indicated that a particular sub-population (Cluster 2) - defined by a substantial weighting on the EPHA1 target - demonstrated a statistically significant association with MMSE scores, relative to cluster 3. These results suggest that data-driven genetic feature engineering provides an interpretable basis for inference regarding variance in global cognition. By discovering multivariate genetic architecture, this modeling approach captures complexity often missed by individual clinical variable modeling. Such findings implicate the utility of interpretable machine learning for translational dementia research and predictive clinical stratification.

Background: Blood-brain barrier (BBB) dysfunction is increasingly recognized as a feature of cerebral amyloid angiopathy (CAA) and has been linked to hemorrhagic imaging manifestations such as cortical superficial siderosis. However, it remains unclear whether neurovascular barrier dysfunction can be captured by routinely available fluid biomarkers and whether such markers identify clinically relevant hemorrhage-prone CAA phenotypes. The CSF/serum albumin quotient (QAlb) is an established marker of neurovascular barrier dysfunction. We investigated QAlb levels in CAA and their association with imaging markers of disease severity. Methods: We included 225 participants (115 with CAA, 72 with Alzheimers disease [AD], 38 healthy controls) with CSF biomarkers and standardized MRI evaluation. Pathologic QAlb levels were identified via the age-corrected Reiber-formula. Group differences and determinants of pathological QAlb were assessed using uni- and multivariable regression analyses. The diagnostic relevance was assessed by receiver operating characteristic analysis. Results: QAlb levels were higher in CAA than in controls (ratio of means [RoM] 1.43, 95% CI 1.28-1.58) and patients with AD (RoM 1.22, 95% CI 1.10-1.35; both p<0.001). Pathological QAlb was independently associated with CAA compared with controls (OR 12.16, 95% CI 2.56-57.86) and AD (OR 2.14, 95% CI 1.07-4.28). Despite these associations, QAlb showed only moderate discrimination between CAA and controls (AUC 0.75, 95% CI 0.67-0.82) and low discrimination between CAA and AD (AUC 0.63, 95% CI 0.55-0.71). Within the CAA cohort, pathological QAlb was independently associated with disseminated cortical superficial siderosis (OR 3.92, 95% CI 1.31-11.72; p=0.014), a marker of advanced hemorrhage-prone disease. Conclusion: QAlb is elevated in patients with CAA and is associated with disseminated cortical superficial siderosis, the strongest predictor of future intracerebral hemorrhage. These findings support an association between neurovascular barrier dysfunction and the hemorrhage-prone phenotype of CAA.

Background: Alzheimer's disease (AD) is characterized by amyloid beta and tau accumulation accompanied by altered inflammatory responses. Sex is an important modifier of AD risk and pathology, however, its influence on relationships between peripheral inflammatory markers and cerebrospinal fluid (CSF) AD biomarkers remains unclear. The aim of this study was to determine whether sex modifies peripheral inflammatory biomarker relationships associated with AD pathology and clinical stage. Materials and Methods: Twelve CSF biomarkers and 41 plasma biomarkers spanning AD pathology, neurodegeneration, and inflammation were measured on the Luminex platform in a cross-sectional cohort of 261 participants from the Cleveland Clinic Lou Ruvo Center for Brain Health Biobank. Associations were evaluated in sex-adjusted, sex-interaction, and sex-stratified models, accounting for age, APOE4 carrier status, and diagnosis. Results: Plasma IL-5 was inversely associated with clinical stage, and 10 plasma inflammatory markers, including Flt-3L, MCP-1, soluble TREM2 (sTREM2), TNF, IL-8, IL-5, IL-12P40, IL-1RA, fractalkine, and G-CSF, were inversely associated with the CSF pTau181/A{beta}42 ratio in pooled models adjusted for sex. Although formal biomarker x sex interactions did not survive FDR correction, significant associations between the CSF pTau181/A{beta}42 ratio and plasma MCP-1 and IL-12P40 were observed in females but not males. Discussion: Our findings identify a group of peripheral inflammatory markers associated with AD pathology and suggest that some of these relationships may vary by sex, warranting larger studies to clarify the role of sex in AD pathobiology.

INTRODUCTION: Tau pathology in Alzheimers disease preferentially afflicts excitatory neurons in the limbic and association cortices that utilize high levels of calcium signaling to perform cognitive operations. This includes the layer III pyramidal cells in the dorsolateral prefrontal cortex (dlPFC) that subserve higher cognition, which express the calcium-binding protein, calbindin, when young and healthy, but lose calbindin and develop tangles and degenerate in Alzheimers disease (AD). These data suggest that loss of calbindin may be associated with the emergence of tau pathology. However, the relationship between calbindin and early-stage, soluble tau pathology is challenging to study in human brains, as soluble pTau dephosphorylates within 15min postmortem. In contrast, the relationship between calbindin and soluble pT217-tau expression can be studied in aging macaques with naturally-occurring tau pathology, where perfusion fixation is possible to capture phosphorylation state in situ. METHODS: The current study used multiple-label-immunofluorescence to label MAP2-positive dlPFC layer III pyramidal cells for calbindin and pT217-tau in macaque brains across the adult age span (8-34.5yrs). The study employed a semi-automated CellProfiler workflow to identify labeled pyramidal cell dendrites the cellular compartment where tau pathology begins in AD. RESULTS: Calbindin expression decreased with age, while pT217Tau increased with age. Specifically, the ratio of calbindin/pT217-tau within a dendrite decreased with age, and was especially prominent in the aged macaques with long-term inflammatory disorders. DISCUSSION: These data suggest that the loss of calbindin in dendrites with advancing age, and especially with inflammation, contributes to the rise of tau pathology and the risk of AD.

Introduction: Mild Cognitive Impairment (MCI) is defined as a decline in one or more cognitive domains worse than expected for age and encompasses several subtypes depending on the cognitive(s) function(s) impaired. Older adults presenting amnestic MCI combined with one or several other impaired domains are the highest at risk of dementia. Yet, no consensual screening method for MCI in community-dwelling older adults has been established. The aim of this study was to identify cognitive aging profiles using multivariate analysis based on three neuropsychological assessments and to characterize profiles consistent with different probable MCI subtypes. Methods: A total of 161 community-dwelling older adults from the 13EVAL cluster-randomized controlled trial performed the Montreal Cognitive Assessment including the Memory Index Score, the Trail Making Test and the Victoria Stroop Test. Hierarchical clustering on principal components was conducted based on four cognitive domains (global cognition, memory, inhibition and cognitive flexibility) and age. Inter-groups comparisons were performed using one-way ANOVA. Individual performances were compared to normative standard for each assessment to characterize each group. Results: Three clusters were identified that differed significantly in age (F2,158=78.56, p<.001, 2p=.50), global cognition (F2,158=96.07, p<.001, 2p=.55), memory (F2,158=81.48, p<.001, 2p=.51), cognitive flexibility (F2,158=52.25, p<.001, 2p=.40) and inhibition (F2,158=12.14, p<.001, 2p=.13). Inter-groups comparisons and comparisons to normative values led to the characterization of Cluster 1 as normal cognition, Cluster 2 as probable executive MCI and Cluster 3 as probable amnestic and executive MCI. Conclusions: Individuals with cognitive profiles consistent with probable executive MCI were identified using simple assessments of global cognition, memory and executive functions in a community-dwelling older population. As participants were not clinically diagnosed, further prospective studies are needed to determine the screening performance of this approach.

ABSTRACT INTRODUCTION: Early identification of individuals with mild cognitive impairment (MCI) at high risk of conversion to Alzheimer's disease (AD) is essential for timely intervention. We evaluated whether routinely obtainable clinical assessments can accurately predict 24-month MC to AD conversion. METHODS: Data from 2,430 participants with MCI in the Alzheimer's Disease Neuroimaging Initiative were analyzed. XGBoost, Random Forest, and Logistic Regression models were evaluated. SHAP-based feature selection and feature ablation analyses assessed the incremental value of APOE4 genotype. RESULTS: A six-feature model incorporating age, sex, education, RAVLT Immediate Recall, MMSE, and EcogSPTotal achieved an AUC of 0.922 (95% CI, 0.911~0.933). APOE4 provided negligible additional predictive value once cognitive measures were included. The XGBoost model outperformed Clinical Dementia Rating Sum of Boxes classification. DISCUSSION: Routine cognitive assessments accurately predict 24-month MCI-to-AD progression without biomarkers, neuroimaging, or genetic testing, offering a practical, low-cost tool for clinical risk stratification.

Background: Epidemiological evidence links type 2 diabetes (T2D) to an increased risk of dementia, including Alzheimers disease (AD). However, previous syntheses often combined heterogeneous diabetes and dementia definitions and have not comprehensively quantified AD incidence among individuals with T2D. We aimed to estimate both the incidence of AD among individuals with T2D and the association between T2D and AD using studies with well-defined T2D and AD outcomes. Methods: We systematically searched MEDLINE, CINAHL (via EBSCO), Embase (via Ovid), and Scopus from inception to April 2026 for studies investigating the incidence of AD among individuals with T2D or the association between T2D and AD. Data were pooled using random-effects models and presented as incidence rates and adjusted relative risks (RRs) with 95% confidence intervals (CIs). Results Of the 9,430 articles identified, 40 studies involving 27,102,559 participants were included. Twenty-three studies contributed incidence data, and 26 reported adjusted relative risks (aRR). The pooled incidence of AD among individuals with T2D was 4.71 per 1,000 person-years (95% CI 3.31, 6.71). T2D was associated with an increased risk of AD (aRR 1.53, 95% CI 1.38, 1.70). Subgroup findings were generally consistent, results were robust in sensitivity analyses, and no publication bias was detected. Conclusions: This study provides a comprehensive quantification of the AD burden associated with T2D by focusing on well-defined AD and T2D outcomes and advancing the field beyond prior broad dementia syntheses. Integrating incidence and relative risk estimates clarifies both the absolute and relative burden of AD in T2D and extends previous syntheses that primarily emphasised relative risk. Individuals with T2D experienced approximately five AD cases per 1,000 person-years and a 53% higher risk of AD, supporting the rationale for integrating cognitive risk prevention into diabetes care.

Introduction: Multimorbidity clusters have been associated with increased dementia risk. While lifestyle factors may modify dementia risk, their role in multimorbidity clusters remains unclear. Method: Data from UK Biobank was used to identify clusters of chronic conditions using latent class analysis, assess their associations with dementia risk using Cox regression, and potential moderating effects of lifestyle factors. Results: We included 465,175 participants (mean age (SD) = 56.52 (8.01), 53.87 % female). Five clusters were identified and significantly associated with increased dementia risk, with the cardiometabolic (HR = 2.14, p < 0.001) and mental health cluster (HR =1.99, p < 0.001) exhibiting the highest risk. Only moderate physical activity lowered dementia risk in the pain-dominated multimorbidity cluster (HR = 0.77, p = 0.039). Discussion: Lifestyle factors including physical activity may protect against dementia in specific multimorbidity clusters. Future research involving objective and multiple lifestyle measures is needed.

Dementia is a progressive neurological condition characterized by cognitive decline and structural brain changes that evolve. Longitudinal modeling of these changes is important for improving disease monitoring, identifying progression patterns, and supporting early risk stratification. This study developed an explainable longitudinal machine-learning framework for dementia progression, using cognitive and Magnetic Resonance Imaging (MRI)-derived biomarkers from the Open Access Series of Imaging Studies (OASIS-2) longitudinal dataset. The dataset included 150 subjects and 373 repeated observations classified as Non-demented, Demented, or Converted. Current-visit features, previous-visit features, and slope-based temporal features were constructed from Mini-Mental State Examination, Clinical Dementia Rating, normalized whole-brain volume, estimated total intracranial volume, atlas scaling factor, Age, and MRI delay. Baseline models were compared with a longitudinal gradient-boosted model, using patient-level splitting to reduce data leakage across repeated visits. The proposed longiGradient Gradient boosting model achieved the best held-out test performance, with an accuracy of 88.16%, a macro F1-score of 0.776, and a weighted F1-score of 0.860. The model showed strong classification performance for Demented and Non-demented individuals, while converted cases remained more difficult to identify. A regularized gradient boosting model was also evaluated as an overfitting sensitivity analysis; although it reduced the perfect training fit, it did not improve held-out test performance. Feature importance, permutation importance, and SHapley Additive exPlanations identified Clinical Dementia Rating as the dominant predictor, with slope-based Clinical Dementia Rating providing additional longitudinal information. These findings suggest that combining cognitive measures, MRI-derived biomarkers, and temporal feature engineering can improve dementia progression modeling, although external validation in larger longitudinal cohorts is needed.

INTRODUCTION: Novel capillary-blood collection methods have not yet been evaluated for a wide range of central nervous system (CNS) and neurodegenerative disease-related proteins. Biomarkers of Alzheimer's disease (AD) and related disorders (ADRD) collected from devices like the Tasso+, a minimally invasive upper-arm capillary blood collection device, must be compared to traditional venipuncture to assess for validity. METHODS: Participants underwent blood collection via traditional venipuncture and Tasso+ in a clinical research setting. The Nucleic Acid Linked Immuno-Sandwich Assay (NULISA) CNS panel was used for biomarker quantification in venous and Tasso-derived plasma. RESULTS: Eighty-three participants (age mean{+/-}SD 76.8{+/-}8.2 years, 79.5% cognitively unimpaired) completed blood collection. Little to no correlation was found between venous and Tasso+ plasma for p-tau217, but the correlation was improved by using a brain-derived (BD)-p-tau217/BD-p-tau181 ratio. Extremely strong correlations were found for neurofilament light (NfL) and glial fibrillary acidic protein (GFAP). Among the 131 biomarkers measured, 51 (38.9%) had a Pearson R [&ge;] 0.90; 27 (20.6%) had values between 0.70-0.90; 26 (19.9%) had values between 0.30-0.70; and 27 (20.6%) had values [&le;] 0.30. DISCUSSION: The Tasso+ accurately measures NfL and GFAP, but caution is warranted when measuring other AD/ADRD biomarkers, as agreement with venous plasma appears to be protein or ratio dependent. These results highlight that important biomarker-specific differences must be considered when translating capillary blood collection approaches. They also further support foundations for development of these methods, highlighting both the opportunities and remaining challenges for translating the promise of blood-based biomarkers beyond AD/ADRD specialty clinics and research settings.

Background: Up to 30% of individuals harboring core Alzheimer's disease (AD) neuropathology, amyloid-beta (Abeta; A) and tau (T)-remain cognitively unimpaired. Objective: We examine whether MRI measures of cerebral blood flow (CBF) and white matter hyperintensities (WMH) differentiate cognitively impaired (AD or mild cognitive impairment (MCI);AD+MCI) from non-demented individuals with (NDAN) and without (Controls) core AD neuropathology. Methods: A retrospective cohort study (2018-2023) using data from The Wisconsin Registry for Alzheimer's Prevention and Wisconsin Alzheimer's Disease Research Center studies employed linear models comparing group differences in regional gray matter (GM) CBF and whole brain WMH volume. Participants (N=500) underwent 3T MRI, amyloid- (11C-Pittsburgh Compound B) and tau- (18F-MK6240) PET, and neuropsychological assessments. We categorized participants based on PET and cognitive status as Controls (n=416; cognitively unimpaired, A-T-), NDAN (n=38; cognitively unimpaired, A+T+), or AD+MCI (n=46; cognitively impaired, A+T+). Results: Participants were 67 years old (mean), 68% female, and 37% APOE 4+. NDAN, like Controls, had significantly higher CBF than AD+MCI in GM regions susceptible to neurofibrillary tangle formation in early AD (frontal and temporal cortices, and limbic regions (ps<0.05)). Largest CBF differences (22-34%) were observed in GM regions that accumulate amyloid early but remain largely tangle-free during early AD progression, namely the occipital and parietal cortices. WMH volume differentiated AD+MCI from Controls (p=0.002) but not NDAN (p=0.16). Conclusion: CBF differentiated NDAN from AD+MCI, highlighting vascular contributions to cognitive resilience. Most pronounced CBF preservation in NDAN was observed in parietal and occipital cortices, regions typically free of tau until late stages of AD progression.

INTRODUCTION: Accurately identifying risk of Alzheimers Dementia (AD) is essential for supporting people living with symptoms in clinical settings, as well as recruiting adults in prospective medical research. Various algorithms have been created to calculate AD risk based on evidenced risk factors which are weighted toward a total score. As daily life conditions determining risk change at scale, it remains unclear how effective gold standard algorithms remain in modern cohorts. METHODS: In the Bio-Hermes-001 diverse cohort, we assessed algorithm discrimination and calibration in six outcomes: classifying AB PET binary outcome (negative N = 603, positive N = 342); phosphorylated tau-217 binary outcome (pTau-217 negative N = 166, positive N = 469); participants with Healthy Cognition (N = 417) from probable AD (N = 272); HC from Mild Cognitive Impairment (N = 312), HC from pooled MCI or AD; and MCI from AD. Approximately a third of the cohort are individuals from populations typically underrepresented in dementia research (HC: 19%; MCI: 24%; AD: 33%). RESULTS: Hosmer-Lemeshow tests and Brier score demonstrate acceptable calibration of all algorithms except the oldest algorithm. However, Receiver Operating Characteristic (ROC) curves and the associated area under the curve (AUC) estimates evidenced that in this cohort only the BDSI exceeded conventional thresholds for good discrimination (.8 AUC in HC-AD classification, with AUC approximately .7 in the other clinical, AB PET, and pTau-217 comparisons). When the functional item is removed from the BDSI score, it remains acceptably calibrated, but DeLong tests reflect statistically significant reduction in discriminatory performance for all group comparisons. The two earliest published algorithms were only chance-level accurate. DISCUSSION: In a contemporary, diverse cohort, most established dementia risk algorithms had limited power in discriminating amyloid positivity, pTau-217 positivity, and current cognitive status despite acceptable calibration. Including a functional measure markedly improved discrimination across both clinical and biomarker-defined outcomes, suggesting that proximal indicators of cognitive vulnerability are critical for identifying individuals with underlying AD-related pathology.